Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- What do we do?
- How do we do it?
- Talk overview
- 1736: Seven bridges in Königsberg
- 1758: Affinity diagrams
- 1864: Constitutional formulae
- 1874: Kenograms & Isomers
- 1878: Chemicographs
- Molecular representations: Adjacency matrix
- Molecular representations: Connection table
- Molecular representations: SMILES
- Molecular representations: 2D chemical structure
- Molecular structure representations (Table)
- Some simple examples of SMILES
- Topology, Topography, Surface & Conformers
- Molecular descriptors
- Physicochemical descriptors
- Lipinski’s rule of 5
- Drug-likeness heuristics
- Molecular fingerprints
- Examples of molecular descriptors
- Molecular similarity (Why it’s important)
- Molecular similarity calculation
- Similarity searching
- High-throughput & Virtual screening
- Enrichment plot
- Statistical learning
- Clustering & Diversity
- Diversity subset selection
- 1868: Properties as function of structure
- Predictive modelling trade-off surface
- Free-Wilson analysis
- QSARs: Physicochemical properties
- QSARs: Molecular fingerprints
- QSARs: The results
- The Importance of de novo design
- Exploration versus exploitation
- In silico medicinal chemistry
- Summary
- In silico medicinal chemistry (Book)
- Bioisosteres and scaffold hopping
Topics Covered
- Graph theory and molecular structure representations
- Molecular descriptors
- High-throughput and virtual screening
- Clustering and diversity selection methods
- QSAR: quantitative structure-activity relationship models
- Multiobjective de novo design
Talk Citation
Brown, N. (2016, December 29). Ligand-based drug design [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/LOMC9706.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Nathan Brown has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Nathan Brown
from the Institute of Cancer Research
in London,
and today I'm going to be talking to you
about computational methods
in ligand-based drug design
for medicinal chemistry.
0:10
So ligand-based drug design -
it's important to understand
what we do and how we achieve it.
So we use computational methods
to design, select and prioritise
synthetic chemistry targets
that will then contribute positively
to a medicinal chemistry project.
0:23
And how we do that is to,
starting from the top,
to identify potential substituents;
if we've got a core
scaffold of interest.
We then can enumerate libraries
in the computer, virtually.
From those libraries of possible
new chemical structures,
we can calculate predictions
in the computer using
empirical models and first principles models.
Then we prioritise compounds,
and then the most time-consuming part
is the chemical synthesis
and biological testing
of those target molecules.
Followed by data analysis
of the resulting data
and then we iterate around that
to design new, more potent,
and more effective drugs.
0:57
So an overview of this talk is,
we're going to cover
molecular representations,
a number of different types
of molecular descriptors
including physicochemical properties
and structural fingerprints.
We'll then move onto concepts
of molecular similarity
and how they're used in virtual screening.
We'll then conclude with some aspects
of statistical learning,
in particular unsupervised learning
and supervised learning.
1:18
So the foundations of modern
computational chemistry
come from graph theory
that was founded as a discipline
in the early 18th century
by Leonhard Euler,
where he tried to understand
a path problem in Königsberg
where you would cross every bridge
in Königsberg only once
and pass each of the land masses.
So Euler started with a map of Königsberg
and then colour coded the landmasses,
each landmass is coloured differently,
with the bridges connecting them
highlighted in blue.
So this map already contains
a lot of redundant information
that isn't necessary
for the problem at hand.
So we can take away the actual map
and we're just left
with the morphology of landmasses
and the connectivity
between these landmasses.
Then we can abstract this even further
because we don't need to know
the morphology of the landmasses,
we just need to know that they exist,
and they're connected.
So we can get rid of morphology
and then we end up
with an abstract graph representation
which led to the foundation
of the mathematical discipline
of graph theory.